Cholangiocarcinoma

The FDA granted accelerated approval to pemigatinib for treatment of certain adults with previously treated unresectable cholangiocarcinoma.

The FDA granted fast track designation to infigratinib for first-line treatment of unresectable advanced or metastatic cholangiocarcinoma who harbor FGFR2 gene fusions or translocations, according to the agent’s manufacturer.

The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer.

Incyte announced positive overall response rate and progression-free survival results for pemigatinib, a selective fibroblast growth factor receptor inhibitor under evaluation for patients who failed previous treatment for advanced or metastatic cholangiocarcinoma, according to a press release.

BARCELONA, Spain — Ivosidenib improved outcomes among patients with isocitrate dehydrogenase-mutated advanced cholangiocarcinoma, according to the results of the randomized phase 3 ClarIDHy study presented at European Society for Medical Oncology Congress.

Results from a systematic review and meta-analysis revealed 13 risk factors for intrahepatic and extrahepatic cholangiocarcinoma, the most significant of which included biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C.